Compugen (NASDAQ: CGEN) and Yield10 Bioscience (NASDAQ:YTEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.
Institutional and Insider Ownership
17.4% of Compugen shares are owned by institutional investors. Comparatively, 4.3% of Yield10 Bioscience shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 11.2% of Yield10 Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Compugen has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Yield10 Bioscience has a beta of 3.43, meaning that its stock price is 243% more volatile than the S&P 500.
This is a breakdown of current recommendations for Compugen and Yield10 Bioscience, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Compugen presently has a consensus target price of $14.00, indicating a potential upside of 418.52%. Given Compugen’s higher possible upside, equities analysts clearly believe Compugen is more favorable than Yield10 Bioscience.
This table compares Compugen and Yield10 Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Compugen and Yield10 Bioscience’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Yield10 Bioscience||$1.16 million||12.57||-$7.60 million||($2.95)||-0.58|
Yield10 Bioscience has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Yield10 Bioscience, indicating that it is currently the more affordable of the two stocks.
Compugen beats Yield10 Bioscience on 8 of the 13 factors compared between the two stocks.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Yield10 Bioscience Company Profile
Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.